SCHEMBL5547598

SCHEMBL5547598

O=[C]CCCCc1ccc(OC(F)(F)C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.37
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN6 P29350 1/20 0.35
PTPN11 Q06124 1/20 0.35
DAO P14920 1/20 0.34
THRB P10828 2/20 0.33
GPR84 Q9NQS5 1/20 0.33
THRA P10827 1/20 0.33
PPARG P37231 2/20 0.32
FAAH O00519 1/20 0.32
SLC6A5 Q9Y345 1/20 0.32
MGLL Q99685 2/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
FFAR1 O14842 1/20 0.31
LTA4H P09960 1/20 0.31
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547968 0.98 PPARA (0.36) PPARAPTPN2PTPN1PTPN6PTPN11
SCHEMBL4609982 0.87 DAO (0.44) PPARADAOGPR84SLC6A5FFAR1
SCHEMBL5546116 0.86 DAO (0.43) PPARADAOGPR84FAAHSLC6A5
SCHEMBL5537169 0.82 DAO (0.46) PPARADAOGPR84SLC6A5FFAR1
SCHEMBL5538675 0.80 PPARG (0.36) PPARAPTPN2PTPN1PTPN6PTPN11
SCHEMBL5546752 0.79 PPARA (0.35) PPARAPTPN1DAOGPR84SLC6A5
SCHEMBL5547603 0.78 PPARA (0.37) PPARAPTPN2PTPN1PTPN6PTPN11
SCHEMBL5547971 0.77 PPARA (0.36) PPARAPTPN2PTPN1PTPN6PTPN11
SCHEMBL2090912 0.77 PPARA (0.37) PPARAPTPN2PTPN1PTPN6PTPN11
SCHEMBL2090914 0.77 MAOB (0.41) PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PPARA 429/4885PTPN2 898/4885PTPN1 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.